Abstract:Background Adjuvant chemotherapy after radical resection of stage IIIA non-small-cell lung cancer (NSCLC) has quite poor outcomes. We aimed to investigate whether adjuvant erlotinib therapy improves 2-year disease-free survival compared with chemotherapy in epidermal growth factor receptor (EGFR) mutation-positive stage IIIA NSCLC. Methods In this randomised, open-label, phase 2 trial, eligible patients aged 18-75 years who had undergone complete (RO) resection of histologically or pathologically confirmed stage IIIA EGFR mutation-positive NSCLC and had not received any previous anticancer therapies were enrolled. Patients were randomly assigned (1:1) to receive either adjuvant erlotinib (150 mg once daily administered orally) or vinorelbine and cisplatin chemotherapy (four cycles of vinorelbine [25 mg/m(2) intravenously on days 1 and 8 of each 21-day cycle] plus cisplatin [75 mg/m(2) intravenously on day 1 of each 21-day cycle]). Randomisation was done by Simon's minimisation with a random element and was stratified by EGFR activating mutation type (exon 19 vs 21), histology (adenocarcinoma vs non-adenocarcinoma), and smoking status (smoker vs non-smoker). The primary endpoint in the unblinded intention-to-treat analysis was 2-year disease-free survival. This ongoing study is registered with ClinicalTrials.gov , number NCT01683175. Findings Between Sept 8, 2012, and May 21, 2015, 102 patients from 16 centres across China were enrolled and randomly assigned to receive erlotinib (n=51) or chemotherapy (n=51). Median follow-up was 33.0 months (IQR 17-8-43-1). 2-year disease-free survival was 81.4% (95% CI 69.6-93.1) in the erlotinib group and 44.6% (26 -9-62- 4) in the chemotherapy group (relative risk 1.823 [95% CI 1.194-2.784; p=0.0054). The difference in 2-year disease-free survival between the groups was 36.7% (95% CI 15 - 5-58- 0; p=0.0007). Adverse events of any grade occurred in 29 (58%) of 50 patients in the erlotinib group and 28 (65%) of 43 patients in the chemotherapy group. Grade 3 or worse adverse events occurred in six (12%) of 50 patients in the erlotinib group versus 11 (26%) of 43 in the chemotherapy group; the most common of these in the erlotinib group was rash (in two 14%1 of 50 patients) and in the chemotherapy group were decreased neutrophil count (in seven [16%] of 43 patients) and myelosuppression (in four [9%]). No treatment-related deaths were reported. Interpretation Adjuvant erlotinib improved 2-year disease-free survival in patients with EGFR mutation-positive stage IIIA NSCLC compared with chemotherapy, with a better tolerability profile. This study suggests that tyrosine kinase inhibitors could have a potentially important role as adjuvant therapy in EGFR mutation-positive stage IIIA NSCLC. However, this trial was a phase 2 study. Mature overall survival data are also needed. Ongoing studies will hopefully confirm the role of adjuvant EGFR tyrosine kinase inhibitor therapy in patients with NSCLC. Copyright (C) 2018 Elsevier Ltd. All rights reserved.

Three-arm Randomised Controlled Phase 2 Study Comparing Pemetrexed and Erlotinib to Either Pemetrexed or Erlotinib Alone As Second-Line Treatment for Never-Smokers with Non-Squamous Non-Small Cell Lung Cancer

Efficacy of Pemetrexed Plus Platinum Doublet Chemotherapy As First-Line Treatment for Advanced Nonsquamous Non-Small-cell-lung Cancer: a Systematic Review and Meta-Analysis.

Pemetrexed and Platinum with or Without Pembrolizumab for Tyrosine Kinase Inhibitor (Tki)-Resistant, EGFR-mutant, Metastatic Nonsquamous NSCLC: Phase 3 KEYNOTE-789 Study

[A Randomized, Controlled, Multicenter Clinical Trial Comparing Pemetrexed/cisplatin and Gemcitabine/cisplatin As First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer].

A Phase II Randomized Trial Evaluating Gefitinib Intercalated with Pemetrexed/platinum Chemotherapy or Pemetrexed/platinum Chemotherapy Alone in Unselected Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer

A phase II randomized trial evaluating gefitinib intercalated with pemetrexed/platinum chemotherapy or pemetrexed/platinum chemotherapy alone in unselected patients with advanced non-squamous non-small cell lung cancer.

Second-line Pemetrexed Versus Docetaxel in Chinese Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer: A Randomized, Open-Label Study

Study of Gefitinib and Pemetrexed As First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation

Prospective Assessment of Pemetrexed or Pemetrexed Plus Platinum in Combination with Gefitinib or Erlotinib in Patients with Acquired Resistance to Gefitinib or Erlotinib: A Phase II Exploratory and Preliminary Study

A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC)

Camrelizumab Plus Carboplatin and Pemetrexed As First-Line Therapy for Advanced Non-Squamous Non-Small-cell Lung Cancer: 5-Year Outcomes of the CameL Randomized Phase 3 Study

Erlotinib Versus Etoposide/Cisplatin with Radiation Therapy in Unresectable Stage III Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer: A Multicenter, Randomized, Open-Label, Phase 2 Trial

Chemotherapy Plus Erlotinib Versus Chemotherapy Alone for Treating Advanced Non-Small Cell Lung Cancer: A Meta-Analysis

Clinical observation of Pemetrexed first-line treatment in advanced non-squamous lung cancer or non-small cell lung cancer without driver-mutations: a phase 2, single-arm trial

Intercalated Combination of Chemotherapy and Erlotinib for Patients with Advanced Stage Non-Small-cell Lung Cancer (FASTACT-2): a Randomised, Double-Blind Trial

Erlotinib Versus Vinorelbine Plus Cisplatin As Adjuvant Therapy in Chinese Patients with Stage IIIA EGFR Mutation-Positive Non-Small-cell Lung Cancer (EVAN): a Randomised, Open-Label, Phase 2 Trial.

Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR -mutant non-small-cell lung cancer: final overall survival analysis of the EMERGING-CTONG 1103 randomised phase II trial

Survival Without Common Toxicity Criteria Grade 3/4 Toxicity Following Second-Line Treatment with Pemetrexed for Nonsquamous Non-Small Cell Lung Cancer in Chinese Patients

Concomitant Chemoradiation Therapy Phase II Study Comparing Pemetrexed/Carboplatin with Paclitaxel/Carboplatin in Patients with Unresectable Stage III Non-small Cell Lung Cancer

Erlotinib-based doublet targeted therapy versus erlotinib alone in previously treated advanced non-small-cell lung cancer: a meta-analysis from 24 randomized controlled trials.

A Randomized Placebo-Controlled Phase III Study of Intercalated Erlotinib with Gemcitabine/platinum in First-Line Advanced Non-Small Cell Lung Cancer (NSCLC): FASTACT-II.